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Amiodarone was used to treat cardiac arrhythmias that
had been refractory to conventional medical therapy.
The first 70 consecutive patients treated with amioda-
rone in this study had at least 6 months of follow-up
(range 6 to 24, mean 11) and form the basis for this
report. Sixty-six patients were treated for ventricular
arrhythmias and four for supraventricular tachycardias.
Amiodarone therapy consisted of a loading dose of
600 mg orally twice a day for 7 days, and 600 mg daily
thereafter. Doses were reduced only if side effects oc-
curred. Because of frequent side effects, the dose was
reduced from S72 ± 283 mg per day (mean ± standard
deviation) at 4S days to 372 ± 174 mg per day at 6
months. With a mean follow-up of 11 months in the S4
patients who continued to take amiodarone, only 4 pa-
tients had ventricular fibrillation. Three additional pa-
tients experienced recurrent sustained ventricular tachy-
cardia in long-term follow-up.
All 70 patients had extensive clinical and laboratory
evaluation in follow-up. Side effects were common, oc-
curring in 93% of patients. Thirteen patients (19%) had
to discontinue the medication because of severe side ef-
Amiodarone is an investigational antiarrhythmic agent that
has been recently introduced in the United States (1-4). It
is a benzofuran derivative with weak alpha- and beta-ad-
renergic blocking effects and was originally tested as an
antianginal drug. It was soon discovered that it had potent
antiarrhythmic effects (5-10). Electrophysiologic properties
of this agent consist of minor slowing of conduction. in-
crease in action potential duration and refractoriness of atrial.
ventricular and His-Purkinje tissue.
Amiodarone is considered to have little negative inotropic
effect, and the occasional hypotension noted with the drug
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feets. Fifty-six patients had gastrointestinal side effects,
most commonly constipation. All patients but 1 even-
tually developed corneal microdeposits, and 43 patients
were symptomatic. Cardiovascular side effects were un-
common. Symptomatic pulmonary side effects occurred
in seven patients, with unequivocal pulmonary toxicity
occurring in five. Neurologic side effects, most com-
monly tremor and ataxia, occurred in S2 patients. Thy-
roid dysfunction occurred in 3 patients, and 32 patients
had cutaneous abnormalities. Miscellaneous other side
effects occurred in 32 patients.
Amiodarone appears to be useful in the management
of refractory arrhythmias. Because virtually all patients
develop side effects when given a maintenance daily dose
of 600 mg, lower maintenance doses should be used. It
is unknown if the more severe side effects are dose-
related. Amiodarone is difficult to administer because
of its narrow toxic-therapeutic range and prolonged
loading phase. More importantly, the first sign of an-
tiarrhythmic failure may be manifest as sudden cardiac
death.
has been attributed to peripheral vasodilation. One of the
primary advantages of amiodarone is its long half-life. but
a disadvantage of this same property is the long time re-
quired for the drug to exert its maximal antiarrhythmic effect
(5).
Although amiodarone has been tested by many investi-
gators and appears to be a good antiarrhythmic agent (II ),
its side effects have been reported to be infrequent (12,13).
Corneal microdeposits appear in virtually all patients treated
with the drug for long periods of time (14). Skin rashes are
less common. but can include both photosensitive dermatitis
and skin discoloration. Thyroid dysfunction (13.15) and
pulmonary toxicity (16-19) have been reported. but have
been uncommon. In addition. minor neurologic side effects
have been noted (20). Side effects seem to correlate with
dosage. but the proper dosage for treatment with amiodarone
is unknown.
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patients had previously undergone coronary artery bypass
graft surgery, 4 had experienced a cerebrovascular accident,
and 10 had a history of chronic obstructive pulmonary disease.
All patients referred for refractory ventricular and supra-
ventricular arrhythmias were considered for amiodarone
therapy. All patients gave informed written consent to par-
ticipate in this evaluation. The protocol was approved by
the Human Subjects Committee at the University of Wash-
ington, beginning August II, 1980.
Amiodarone protocol (Table 3). Patients were initially
screened with a number of laboratory examinations before
the institution of amiodarone therapy. Routine examination
included history and physical examination, 12 lead electro-
cardiogram, chest X-ray examination, 24 hour ambulatory
electrocardiographic (Holter) monitor, pulmonary function
tests, thyroid function tests, radionuclide ventriculogram,
slit lamp corneal examination, routine blood chemistry de-
terminations and unnalysis and liver function tests.
Amiodarone therapy started with a dose of 600 mg orally
twice a day administered for 7 days as an inpatient. The
maintenance dose of amiodarone was then 600 mg daily
thereafter. Because amiodarone requires such a long loading
phase, patients were commonly left on the conventional
antiarrhythmic drug that had been found to be the most
efficacious in suppressing their arrhythmias to that time,
That conventional drug was continued for 4 to 8 weeks after
institution of amiodarone therapy, at which time the con-
ventional drug was stopped to determine arrhythmia control
with amiodarone alone.
Amiodarone dosage was decreased on the basis of side
effects or increased if arrhythmias recurred after the initial
7 day loading phase (Fig. 1). Patients exhibiting good ar-
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We report our experience with both the antiarrhythmic
effects and the common side effects in our first 70 consec-
utive patients treated with amiodarone.
Methods
Patient population. Between August 1980 and Decem-
ber 1982, a total of 130 patients were started on amiodarone
therapy because of symptomatic and refractory cardiac ar-
rhythmias, All patients had failed to benefit from conven-
tional antiarrhythmic agents (quinidine, procainamide, dis-
opyramide and propranolol) either because of inefficacy or
side effects, Inefficacy of conventional drugs was deter-
mined either by spontaneous recurrence of the clinical ar-
rhythmia, ventricular tachycardia on Holter ambulatory
electrocardiographic monitoring or electrophysiologic test-
ing by programmed electrical stimulation. Some patients
were not given disopyramide or propranolol because of
preexisting severe congestive heart failure. Conventional
drugs had been given in progressively increasing doses until
side effects appeared or until the drugs were found to be
ineffective at high therapeutic serum levels. Many patients
had also been given other experimental antiarrhythmic agents,
and conventional drugs had commonly been used in com-
bination with other experimental agents (Table I). Because
of the reported length of time necessary for amiodarone to
exert its full effect. it was commonly reserved as a last
resort drug for use in patients who had failed therapy with
other experimental antiarrhythmic agents that have a shorter
half-life.
In the first 130 patients started on amiodarone, at least
6 months of follow-up were available on the first 70 con-
secutive patients treated with this drug. These 70 patients
form the basis for this report. Mean follow-up for these 70
patients was II months (range 6 to 24),
Patients were referred for a variety of clinical arrhythmias
(Table 2). They ranged in age from 32 to 78 years (average
59). There were 56 men and 14 women. Fifty of the 70
patients had clinical evidence of coronary artery disease; 21
Table 1. Previously Used Ineffective Drugs
Panents
Nu. %
QUinidine 69 99
Procamamide 70 100
Disopyramidc 32 46
Propranolul 20 29
Phenytoin 5 7
Apnndmc 17 24
Mexiletine 13 19
Tocarrude 3 4
Clofilium 3 4
Bretylium 10 14
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Table 2. Clinical Features of 70 Patients
Diagnose,
Cluneal
Coronary artery disease
Cardiumyopathy
Valvular disease
Wolff-Parkinson-Whue syndrome
Mitral valve prolapse
Arrhythmia
Ventncular fibrillation
Single episode
Recurrent
With recurrent sustained
ventncular tachycardia
Ventncular tachycardia
Recurrent sustained
Recurrent unsustained
Single episude sustained
Supraventricular tachycardia
1115
Patient,
(no )
50
9
6
3
2
32
25
7
16
34
29
3
2
4
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Tab le 3. Armodarone Protocol
Months
Before Drug I Wk 2 3 6 9 12 15 18 21 24
History x x x x x x x x x x )( x
Physical examination x x x x x x x x x x x x
Electrocardiogram x x x x x x x x x x x x
Chest X-ray fi lm x x x x x
Holter monitor recording x x x x x
Slit lampcorneal examination x x x
Thyroid function tests x x x x x
Liver function tests x x
Pulmonary function tests x x x x x x
Radionuchde ventriculogram x x
AMIODARONE DOSING
1200 ' 0
Figure 1. Amiodarone dosage versus time. Amiodarone was ini-
tially started at 1,200 rng orally daily, then reduced to 600 mg
daily . The dose was reduced only if side effects appeared. Doses
are depicted as mean ± standard deviation. Numbers at each value
indicate number of patients.
care unit or in the telemetry unit until their arrhythmias
appeared to be stable.
Spontaneous failures early in the course of therapy (within
the first month ) were not considered to be indications for a
change in therapy. The drug was considered to be a failure
only if arrhythmias recurred when severe subjective side
effect s limited an increase in dosage or if arrhythmias (such
as sudden cardiac death or sustained ventricular tachycardia)
recurred in the presence of moderate to heavy corneal mi-
crodeposits of amiodarone which suggested adequate total
body stores of the drug .
Clinical follow-up. Antiarrhythmic effect was classified
on the basis of the presence or absence of sudden cardiac
death, sustained ventricular tachycardia requiring cardio-
version . nonsustained ventricular tachycardia causing symp-
toms of syncope or presyncope and asymptomatic arrhyth-
mias (including nonsustained ventricular tachycardia) as
documented on Holter ambulatory electrocardiographic
monitoring. Because most patients had rece ived all con-
ventional and many experimental antiarrhythmic agents, there
was great pressure to continue amiodarone. Patients who
stopped the drug usually had to return to combinations of
previously unsuccessful antiarrhythmic agents or proceed to
surgica l therapy. Therefore, in general, any side effects that
caused discontinuation of the drug were severe. Side effect s
were classified as mild if no dosage adjustment of amio-
darone was necessary, moderate if the dose had to be low-
ered and severe if the drug had to be temporarily or per-
manently discontinued.
ElectrophysioIogic st udies. Initially all patients had
electrophysiologic testing before amiodarone administra-
tion . Patients were studied in the postabsorptive state, either
nonsedated or lightly sedated with diazepam. One to four
multielectrode catheters were inserted in the femoral and
antecubital veins and positioned fluoroscopically (average
skin dose of radiation = 1.2 rads) . Lidocaine I% local
anesthesia was used, and lidocaine levels were measured at
the time of stimulation. In no case was the lidocaine level
in a therapeutic range. Patie nts were anticoagulated with
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rhythmia control without side effects were left on a 600 mg
daily schedule. In patients exhibiting unequivocal side ef-
fects , the dose was decreased to 400 mg , then if necessary
to 200 mg per day . Occasionally patient s temporarily dis-
cont inued the drug and restarted it at a lower dose . Patient s
who had spontaneous recurrence of severe arrhythmias (ven-
tricular tachycardia) in the first month after institution of
therapy commonly had the dose increased transiently to 600
mg twice a day for another 7 days to 3 months. until ar-
rhythmia control was obtained or side effects appeared.
After initial experience with the drug, during which time
we noted elevations in serum quinidine and procainamide
levels concomitant with the institution of amiodarone (2 1),
patients routinely had daily determinations of serum levels
of quinidine. procainamide and digoxin , if they were taking
any of these medications, and prothrombin time if they were
taking anticoagulants.
Follow-up examinations were performed freque ntly (Ta-
ble 3). Patients were cont inuously monitored in the coronary
l ACC Vol. 2. No 6
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heparin. Right ventricular pacing was performed in at least
two sites and at least three basic cycle lengths, usually 600,
500 and 450 ms. Single and double ventricular extrastimuli
and burst pacing were used in an attempt to induce ven-
tricular tachycardia.
The first patients in the series were tested only a few
days or weeks after institution of amiodarone therapy before
it was realized that a longer loading phase might be nec-
essary for full drug effect. Subsequent patients were tested
only after documentation of the presence of corneal micro-
deposits. usually 2 to 3 months after starting the therapy.
One patient was studied less than I week after institution
of therapy; 17 patients were studied I or more months. 13
patients 2 or more months and 8 patients 3 or more months
after institution of therapy.
Ambulatory electrocardiographic monitoring. Holter
monitoring was performed with two channel Oxford Med-
ilog recorders and analyzed with a Reynolds Pathfinder II
system. The system was interfaced with a Honeywell 1856-
A fiberoptic recorder for continuous printout of all electro-
cardiographic complexes. All episodesof ventricular tachy-
cardia were played in real time for further analysis. The
technician has been documented to be 95% accurate using
this system as compared with hand-counted tapes played in
real time.
Arrhythmias were classified by severity. f requency and
percentage of half-hour intervals containing each arrhyth-
mia . Ventricular tachycardia was defined as three or more
consecutive ventricular complexes at a rate of greater than
100 beats/min.
Electrocardiograms were evaluated in detail fo r the fo l-
lowing variables: sinus rate, PR and QT intervals, QRS
duration, presence of U waves and arrhythmia.
Radionuclide ventriculograms. Standard techniques
were used for analysisof radionuclide ventriculograms. The
radionuclide used was technetium-99m pertechnetate with
stannous pyrophosphate-labeled red blood cells, 25 mCi per
dose, yielding a dose of 0.42 rad (total body) and 1.38 rad
(blood). These tests were analyzed for both right and left
ventricular ejection fractions. Reproducibility of this tech-
nique in our laboratory of two left ventricular ejection frac-
tions acquired and measured on the same day is ± 0.03
(standard deviation).
Pulmonary function tests. Pulmonary function tests were
performed by standard techniques. Measurements routinely
obtained were total lung capacity. diffusioncapacity, forced
vital capacity (FVC), residual volume, I second forced ex-
piratory volume (FEVd and FEV\/FVC. Reproducibility in
the pulmonary function laboratory with these tests is ± 5%
on the same patient on the same day and ± 15% on the
same patient on different days. All tests were performed in
the same laboratory to assure comparability of measurements.
Thyroid function tests. The following measurements
of thyroid function were performed by standard methods:
triiodothyronine (T3) by resin uptake, thyroxine (T4) by
radioimmunoassay and thyroid stimulating hormone (TSH).
Slit lamp corneal examinations. Slit lamp corneal ex-
aminations were performed to assess amiodarone corneal
microdeposition. Corneal microdeposits were classified as
absent, faint, moderate or heavy. Examinations were per-
formed at least at 2 months and every 6 months and com-
monly at more frequent intervals as clinically indicated.
Hepatic function tests. Standard serum tests for hepatic
function included total bilirubin, glutamic oxaloacetic trans-
aminase (SGOT), alkaline phosphatase. glutamic pyruvic
transaminase (SGPT) and lactic dehydrogenase (LDH).
Antiarrhythmic drug levels. Amiodarone levels were
unavailable at the time of the study. After it was recognized
that there might be an interaction between amiodarone and
other drugs, serum trough levels of the quinidine. procain-
amide and digoxin were measured every day for the first 3
days of amiodarone therapy and every other day thereafter
as indicated. Serum levels of these drugs were analyzed by
the standard radioimmunoassay methods. Likewise. pro-
thrombin times were measured daily for all patients taking
coumadin until it appeared that the prothrombin time was
stable.
Statistical analysis. Data were compared using Stu-
dent' s t test for paired and unpaired data, chi-square analysis
and Kaplan-Meier product limit estimates of survival as
appropriate. Probability (pl values less than 0.05 were con-
sidered significant.
Results
Clinical antiarrhythmic efficacy. In a follow-up of 6
to 24 months (mean II ), recurrences of the sudden cardiac
death syndrome or symptomatic sustained ventriculartachy-
cardia requiring cardioversion were uncommon (Table 4).
Ventricular fibrillation . Three patients died of ventric-
ular fi brillation, and another patient had ventricular fibril-
lation and was resuscitated successfully. One of these pa-
tients (Case 50) had been taking400 mg of amiodarone daily
for 2 months after the initial loading schedule. She remained
asymptomatic, and slit lamp corneal examination at 2 weeks
showed no deposits. Her ambulatory electrocardiogram con-
tinued to show multiform and paired ventricular premature
beats but no ventricular tachycardia before the ventricular
fi brillation. A second patient (Case 6) died in the hospital
of ventricular fibrillation. She received the standard loading
dose of 1,200 mg daily for I week and was then maintained
on 600 mg daily. After 4 weeks, the dose was decreased
to 400 mg daily because of severe constipation. Her ep-
isodes of ventricular fibrillation then recurred, and she died
3 months after starting the therapy. A third patient (Case
40) died suddenly after 9 months of taking 400 mg daily.
Her ambulatory electrocardiogram continued to show non-
sustained ventricular tachycardia. Higher doses of amio-
darone were not tolerated because of constipation and skin
rash. Anotherpatient (Case 16) who had ventricularcouplets
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200 8 None
Surgery 2 None
Surgery 4 None
Surgery 4 None
800* 4 None
600t 15 None
Surgery 8 None
400 5 None
400 13 None
Table 4. Arrhythmia Recurrence on Amiodarone
At Time of Arrhythmia
Type of DoselDay Duration of
Case Arrhythmia (mg) Therapy (mo)
6 VF 400 3
40 VF 400 9
50 VF 400 2
64 VF, resus 1200 5 day,
16 VT, sust--+VF, resus 800 14
18 VT, sust 600 14
22 VT, sust 600 1.3
56 VT, sust 400 5
5 VT, nonsust- 600 9
symptomatic
46 VT, nonsust- 900 3
symptomatic
4 VT, nonsust- 400 19
asymptomatic
20 VT, nonsust- 600 1.5
asymptomatic
DoselDay
(mg)
Subsequent Course
Duration of
Therapy (rno) Arrhythmias
*Quinidine added to regimen. t Propranolol added to regimen.
Nonsust == nonsustained: resus = resuscitated; sust = sustained; VF = ventncular fibrillation; VT = ventricular tachycardia; - = patient died
on ambulatory monitoring developed sustained ventricular
tachycardia, followed by ventricular fibrillation, from which
he was resuscitated, An additional patient (Case 64) had
ventricular fibrillation on the fifth day of amiodarone load-
ing. He was successfully resuscitated, and amiodarone load-
ing was continued. He was monitored for 3 additional weeks
before hospital discharge, and has been well without re-
currence of arrhythmias since then.
Sustained ventricular tachycardia. Three other patients
have had a recurrence of sustained ventricular tachycardia,
The arrhythmias were slow enough to be well tolerated
hemodynamically but required electrical cardioversion. All
of these patients had corneal microdeposits, and they had
been on the drug for 5, 1.3 and 14 months at the time of
their recurrence, One patient then had the dose increased
from 400 to 800 mg daily and subsequently had quinidine
readded to his regimen without further recurrence of his
arrhythmias. The other two patients, who had been taking
amiodarone, 600 and 800 rng/day, could not have the dose
increased further. One of these two patients had postural
hypotension and ataxia with a higher dose, and the other
patient developed a peripheral neuropathy, proximal muscle
weakness and abnormal liver function tests requiring ter-
mination of the therapy. Both of these latter two patients
subsequently had surgery for their arrhythmias.
Nonsustained ventricular tachycardia. Four patients had
recurrence of nonsustained ventricular tachycardia, Two of
the patients were asymptomatic from this rhythm, but the
other two patients had near syncopal episodes with their
arrhythmias. One of the symptomatic patients (Case 5) could
not have the dose increased further because of constipation
and symptomatic corneal microdeposits. Propranolol was
added to this patient's regimen. The other symptomatic pa-
tient (Case 46) had neurologic side effects and postural
hypotension at higher doses of amiodarone, so cardiac sur-
gery was performed with electrophysiologically-directed
aneurysm resection. Of the two patients who were asymp-
tomatic from their nonsustained ventricular tachycardia, one
patient could not have the dose of amiodarone further in-
creased because of symptomatic heavy corneal microde-
posits, and the other patient had to have his dose decreased
because of worsening of pulmonary function tests suggest-
ing early pulmonary toxicity. None of these four patients
has had recurrence of nonsustained ventricular tachycardia,
sustained ventricular tachycardia or sudden cardiac death.
Deaths from nonarrhythmic causes. Nine further pa-
tients have died of nonarrhythmic causes during follow-up
while taking amiodarone. Patient 2 had further progression
of his severe heart failure and died in cardiogenic shock 4
months after starting amiodarone therapy. His terminal ad-
mission was prompted by his decision not to take his di-
uretics, rapid accumulation of 20 pounds (kg) of edema
fluid and electrolyte imbalance. His terminal rhythm in car-
diogenic shock was a relatively slow ventricular tachycardia
at a rate of 110 beats/min. Patient 3 likewise died of car-
diogenic shock after slow progression of a low output syn-
drome 3 weeks after starting amiodarone therapy. He died
with a slow idioventricular rhythm and even terminally did
not have either ventricular tachycardia or ventricular fibril-
lation. Patient 7 also died from worsening congestive heart
failure with an idioventricular rhythm as the terminal rhythm
2 months after starting amiodarone. Patient 8, who had
suffered two previous myocardial infarctions without chest
discomfort, developed worsening congestive heart failure
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Figure 2. Kaplan-Meier life table analysis of recurrence of sus-
tained ventncular tachycardia (VT) or ventricular fibrillation (VF).
Patients who continued amiodarone are compared with those pa-
tient, who stopped amiodarone because of noncardiac side effects.
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Discontinuation of amiodarone because of toxic ef-
fects. Thirteen patients discontinued amiodarone because
of side effects (Table 5). These patients were subsequently
followed up for a mean of 8 months. and four of these
patients had either ventricular fibrillation or sustained ven-
tricular tachycardia after amiodarone was discontinued. These
patients could be considered to be of a possible controlgroup
for the amiodarone patients because the medication was
discontinued due to noncardiac side effects. not poor ar-
rhythmia control. All of these patients were subsequently
started on another therapy. 12 patients on the best alternate
medical therapy and I patient on surgical therapy. This
group with severe amiodarone toxicity consisted of 12 pa-
tients with ventricular arrhythmias and I patient with supra-
ventricular arrhythmias. Of the patients with ventricular ar-
rhythmias. there was a 33% incidence of sustained ventricular
tachycardia or ventricular fibrillation (4 of 12) in 8.5 months.
whereas after I week of loading therapy the amiodarone
group had only a 13% (7 of 54) incidence of sustained
ventricular tachycardia or ventricular fibrillation in II months
(p = 0.009. Kaplan-Meier life table. Fig. 2). If only ven-
tricular fibrillation after the first week of therapy is consid-
ered. 2 (17o/c) of the 12 patients who stopped amiodarone
because of side effects had ventricular fibrillation in 8.5
months follow-up. whereas only 4 (7o/c) of the 54 patients
who continued amiodarone had ventricular fibrillation in II
months of follow-up (p = 0.2, Kaplan-Meier analysis. Fig.
3).
Electrophysiologic studies. In all patients ventricular
tachycardia was inducible both before and after amiodarone,
with an average cycle length of 269 before and 305 ms after
amiodarone. In an additional two patients, ventricular tachy-
cardia rapidly degenerated to ventricular fibrillation. After
and abdominal pain 36 hours before death. The mechanism
of his death is unknown, and an autopsy was not performed.
Patient 32 died of probable amiodarone pulmonary tox-
icity. though he also had a recent pulmonary embolus and
myocardial infarction. Patient 42 died of progressive un-
controllable congestive heart failure. Patient 47 had severe
hepatic disease before institution of amiodarone therapy.
Even before amiodaronetherapy, he had intermittent hepatic
encephalopathy. but was also having recurrent ventricular
fibrillation. unresponsive to conventional and other exper-
imental antiarrhythmic agents. Three months after institu-
tion of amiodarone therapy. he died of hepatic encephalo-
pathy. His arrhythmias had been controlled. but the dose had
been progressively decreased. fearing that it worsened his
hepatic function which was marginal even before the drug.
Patient 48 died of a pulmonary embolus. Patient 58 died of
progressive renal failure and electrolyte imbalance. which
was thought to be unrelated to amiodarone.
Supraventricular tachycardia. Of four patients treated
with amiodarone for supraventncular arrhythmias. the drug
was discontinued in one (with recurrent atrial fibrillation)
due to inefficacy, and in one (with Wolff-Parkinson-White
syndromeand atrial fibrillation) because of side effects. Two
other patients (both with Wolff-Parkinson-Whitesyndrome)
have continued therapy with good antiarrhythmic control.
• Treatment termmated by patient. physicrans did not attribute this
symptom to armodarone t Finding later determined not to be due to
armodarone.
Sust = sustained: VF = ventncular fibnllanon. VT = ventncular
tachycardia.
Period
Without
Armodarone Spontaneous
Major Therapy Arrhythmias Since
Case Side Effects (rno) Arrnodarone Discontmuation
I Myoclonus 24 VT. su-t. multiple episode-
<} Agranulocytosis" 3 VF
II Herrubalhsrnus 20 None after surgery for
VTIYF
12 Fatigue. memory 10" 4 None
13 Wheezing" <} VF
IX Neuropathy. thyroid 5 None after surgery for VT
dysfunction
23 Thyroid dysfunction, 10 VT. suvt, multiple epivodes
skin rash
25 Pulmonary toxicity 7 None
3X Pulmonary toxrcrty. 3 None
neuropathy.
thyroid dysfunction
52 Pulmonary toxicrty 2 None
53 Headachev. fangue lJ None
60 Tremor, lJ None
62 Pulmonary toxicity None
Table 5. Patients Who Discontmued Amiodarone Therapy
Because of Side Effects
II 20 GREENE ET AL.
AMIODARONE TOXICITY
l ACC Vol 2. No 6
December 1983.111 4- 28
O+-..,.-....,.-....,.---r-...,-...,~...,-...,,.Lo
o 90 180 270 360 450 540 630 720
Days 01 Followup
Figure 3. Kaplan-Meier life table analysis of recurrence of ven-
tricular fibrillation (VF). Patients who continued amiodarone are
compared with those patients who stopped amiodarone because of
noncardiac side effects.
before amiodarone administration, the difference was not
statisticallysignificant(0.05 < p < 0.10). Therefore, it was
difficult to tell which patients would do poorly on amio-
darone on the basis of total counts of premature ventricular
complexes.
Severity of arrhythmia . Likewise, classification of ar-
rhythmia was not particularly helpful in determining which
patients would do well and which would do poorly. Seven
patients had ventricular tachycardia on the routine follow-
up Holter recording. Three of these patients have been free
of ventricular tachycardia. two patients have had either ven-
tricular fibrillation or sustained ventricular tachycardia and
two patientshave had recurrenceof nonsustainedbut asymp-
tomatic ventricular tachycardia. Fifty patients have had no
ventricular tachycardia on their amiodarone routine follow-
up Holter recording while taking amiodarone: 45 of these
have had no recurrence of symptomatic arrhythmias, 4 pa-
tients have had either ventricular fibrillation or sustained
ventricular tachycardia and one patient has had recurrence
of asymptomatic and nonsustained ventricular tachycardia.
Of the six patients with either ventricular fibrillation or
sustainedventriculartachycardia duringfollow-up , only two
had ventricular tachycardia on their amiodarone follow-up
Holter recording. Two other patients had no arrhythmias
whatsoever; one patienthad multiform prematureventricular
complexes and couplets. and one patient had multiform
single premature ventricular complexes. Of the three pa-
tients with nonsustained ventricular tachycardia in follow
up, two had ventricular tachycardiaon their routine follow-
up Holter recordingand one patienthadonly couplets. Three
of the other 48 patients had ventricular tachycardia on the
routine amiodarone follow-up Holter recording and all of
these 48 patients havebeenfree of arrhythmias, subsequently.
Therefore, from this small group of patients it is difficult
to predict from the Holter monitor recording which patients
will have significant arrhythmias on follow-up. There is a
weak trend suggesting that patients who have high density
premature ventricular complexes on the control Holter re-
cording and who exhibit a dramatic decrease in the pre-
mature ventricular complex counts will do better, whereas
those patients who have fewer premature ventricular com-
plexes on control Holter recording and who actually have
an increase in their premature ventricular complex counts
will do worse.
Electrocardiographic effects. Amiodarone commonly
changed the electrocardiogram in a characteristic manner
(Table 6). Heart rate decreased, PR interval lengthened,
QRS interval lengthened , QT interval lengthened and large
U waves commonlyappeared. Though patients were usually
taking other antiarrhythmic drugs at the time of the control
electrocardiogram that alone would tend to lengthen the
electrocardiographic intervals, these drugs were commonly
discontinued in the early months of amiodarone therapy.
Cessation of these other antiarrhythmic drugs would have
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- - - Discontinued Amiodarone
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evaluation of these initial 18 patients on amiodarone alone,
other reports appeared (22,23) suggesting that virtually all
patients could still have ventricular tachycardia induced while
taking amiodarone. Therefore, because our experience was
confirmatory of these other reports, we elected to pursue
evaluation of these patients more intensively by Holter am-
bulatory electrocardiographic monitoring.
Holter ambulatory electrocardiographic monitoring.
Because most of these patients were critically ill with on-
going malignantventriculararrhythmias, the monitoring ob-
tained before amiodarone therapy was always obtained while
the patient was being treated with the best antiarrhythmic
agent or combination thereof which had been beneficial in
that patient before the use of amiodarone . Commonly these
control recordings were also obtained on intravenous an-
tiarrhythmic agents.
Number ofpremature ventricularcomplexes . Eventhough
patients were taking other antiarrhythmic agents at the time
of the control monitoring , the switch to amiodarone resulted
in a trend toward a decrease in arrhythmia. Patients had a
mean of 1,228 ± 2,677 premature ventricular complexes
before and a mean of 238 ± 408 after amiodarone therapy
(0.05 < P < 0.10). Patients who subsequently had either
ventricular fibrillation or sustained ventricular tachycardia
in follow-up on amiodarone had a mean of 296 ± 538
premature ventricular complexes on the control Holter re-
cording and 347 ± 477 on the follow-up recording (p =
NS). Other patients who had no significant arrhythmias on
follow-up (including those with nonsustained ventricular
tachycardia)had 1,377 ± 2,856 prematureventricularcom-
plexes on the control Holter recording and 221 ± 404 on
the amiodarone recording (0.05 < P < 0.10). Though the
patients who had no significant arrhythmias on follow-up
had a higher density of premature ventricular complexes
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tended to shorten the sinus interval, QRS duration and PR
and QT intervals.
The decrease in heart rate due to amiodarone was not
symptomatic in any patient, although some patients devel-
oped a heart rate of less than 50 beats/min, One patient had
preexisting profound sinus bradycardia with rates as low as
30 beats/min, and the patient's chronic fatigue was treated
with a permanent pacemaker. However, amiodarone did not
worsen her preexisting sinus bradycardia or congestive heart
failure. Another patient had profound sinus bradycardia with
junctional escape rhythms. His junctional rate was com-
monly in the 40s, and amiodarone reduced his heart rate to
the low 40s or upper 30s. In addition, his heart rate was
less responsive to exercise than it had been before amio-
darone therapy. Two other patients developed mild sinus
bradycardia with heart rates unresponsive to exercise.
Effects on ventricular function. Radionuclide left ven-
tricular ejection fraction averaged 0.40 ± O. 14 before amio-
darone therapy; the minimal value was 0.10 and the max-
imal was 0.87. After 6 to 12 weeks of amiodarone therapy,
the minimal left ventricular ejection fraction was O. 12, max-
0.86 and the mean 0.41 ± 0.16. This change in ejec-
tion fraction was not significant (n = 57, paired t test). The
majority of the other 13 patients not included in this paired
analysis had amiodarone discontinued or died before it was
time for the follow-up determination of left ventricular ejec-
tion fraction.
Right ventricular ejection fraction was less commonly
determined, being measured before and after amiodarone in
30 patients. The mean right ventricular ejection fraction was
0.39 ± 0.14 before and 0.39 ± 0.13 after amiodarone
therapy. The maximal and minimal right ventricular ejection
fractions were 0.92 before and 0.15 and 0.64 and 0.16 after
amiodarone, respectively.
Clinical congestive heart failure. Though the mean left
ventricular and right ventricular ejection fractions were un-
changed, nine patients continued to have clinical deterio-
ration of left ventricular function during amiodarone ther-
apy. Six of these nine patients had New York Heart As-
sociation (NYHA) functional class III congestive heart fail-
ure and 3 had class II heart failure before institution of
amiodarone. At some time during the therapy, the dose of
Table 6. Electrocardiographic Effects of Amiodarone
* 2 to 6 months after initiation of amiodarone therapy
p = probability.
Heart rate (beats/rnm)
PR intervalts)
QRS duranonts)
QT interval(s)
Before
Amiodarone
72 ± 12
0.19 ± 0.03
0.11 ± 0.003
0.43 ± 0.06
After
Amiodarone*
65 ± II
0.21 ± 0.04
0.12 ± 0.04
0.46 ± 0.07
p
< 0001
< 0 001
< 0.005
< 0001
amiodarone was reduced in all nine patients because of the
fear that the drug had contributed to the worsening of left
ventricular function. It is uncertain whether amiodarone pre-
cipitated worsening of congestive heart failure or if these
patients were simply manifesting progression of their in-
trinsic disease. Changes in ejection fraction in individual
patients could not be explained by the duration of amio-
darone therapy or dose of amiodarone.
Thus, congestive heart failure was new or worse in 9 of
the 65 patients in whom left ventricular ejection fraction
was measured before amiodarone therapy. If the initial left
ventricular ejection fraction was 0.35 or less, 7 patients had
new or worse congestive heart failure and 23 patients re-
mained unchanged. If the initial left ventricular ejection
fraction was more than 0.35, 2 patients had worsening or
new congestive heart failure, and 33 patients were un-
changed (p < 0.05).
Postural hypotension. Two patients developed some
postural hypotension when amiodarone was combined with
either quinidine or procainamide, and the blood pressure
returned to normal when either quinidine or procainamide
was discontinued.
Therefore, it appears that amiodarone does not consist-
ently change left ventricular ejection fraction, though the
risk of new or worsening congestive heart failure is greater
in patients whose initial left ventricular ejection fraction is
0.35 or less.
Pulmonary complications. Pulmonary function tests in
this entire group of patients were unchanged. Total lung
capacity decreased only from 97 ± 20 to 94 ± 19% of
predicted; diffusion capacity decreased from 93 ± 25 to 88
± 30% of predicted and FEY I/FYC increased from 76 ±
10 to 78 ± 9% of predicted. However, none of these changes
reached statistical significance. These pulmonary function
tests were performed a mean of 5.6 ± 3.2 months after
initiation of amiodarone therapy. No other changes were
made in other medications known to affect pulmonary per-
formance, and all but one patient had evidence of corneal
microdeposits by slit lamp examination at the time of the
follow-up measurements. Patients were taking a mean dose
of 7.2 ± 2.4 mg/kg body weight.
Syndrome of amiodarone pulmonary toxicity. This syn-
drome is poorly defined. It has usually been characterized
as a constellation of cough, dyspnea on exertion, fever,
infiltrates on chest X-ray examination and decreased dif-
fusion capacity and total lung capacity. It has been described
as a restrictive process, with pathologic features of pul-
monary fibrosis. However, it is not entirely a restrictive
process, and it can occur acutely.
In our 70 patients, there were five patients with unequi-
vocal amiodarone pulmonary toxicity and another six pa-
tients who had possible amiodarone pulmonary toxicity (Ta-
ble 7). These complications occurred between 3 and 13
months of the initiation of therapy without much warning.
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Ta ble 7. Amiodarone Pulmonary Toxicity
Amiodarone Therapy Preamiodarone
Chest X-ray
Case Dose (rug/kg) Durat ion (rno) DLCO TLC FIlm*
Patients With Definite Toxrcity
25 6.7 3 77 98 1+
32 8.5 13 11 0 68 0
37 8.5 12 70 96 1+
52 9A 8 70 110 1+
62 15.6 7 72 93 1+
Patients With Possible Toxicity
20 lOA 9 80 106 1+
22 75 6 79 109 1+
34 12.0 9 127 107 0
35 54 6 77 77 0
38 5.9 9 48 78 1+
69 5.5 5 92 100 0
* Degree of interstiual changes on baseline chest X-ray film. graded O. I + . 2+ . 3+ and 4 +
DLCO = pulmonary diffusion capacity. TLC = tolallung capactty
The syndrome in these five patients was characterized by
abrupt appearance of cough and dyspnea on exertion as-
sociated with new pulmonary infiltrates and diffuse rales.
Patients were often treated either for pulmonary edema or
viral or bacterial infection at other hospitals before it was
recognized that these changes were probably due to the
amiodarone. The pulmonary infiltrates were commonly pe-
ripheral, involving the lower lung fields. It was difficult to
distinguish between pulmonary infection. pulmonaryedema
and amiodarone toxicity, and it was often the subsequent
course that confirmed the diagnosis: lack of sputum pro-
duction, negative cultures, lack of response to antibiotics
and low pulmonary capillary wedge pressure.
One patient (Case 32) in this group of 70 pat ients died
5 days after presentation with worsening dyspnea. He ex-
perienced significant congestive heart failure before this time.
and it was thought that many of his symptoms could be
attributed to his congestive heart failure. However, diuresis
of 2.7 kg of fluid did not improve his dyspnea. and the
chest roentgenogram showed progressive worsening during
this time. Pulmonary capillary wedge pressure was 6 mm
Hg, and the patient subsequently died when adequate oxy-
genation could not be maintained. On postmortem exami-
nation he had a huge heart, congested lungs, evidence of
multiple small pulmonary emboli. a new occlusion of a small
branch of the right coronary artery. pulmonary changes of
alveolar septal thickening and proliferation of alveolar clear
cells filling the air spaces.
Amiodarone pulmonary toxicity occurred either early or
late in patients taking as little as a 200 mg daily maintenance
dose. although two patients were taking 600 mg daily. and
two patients were taking 800 mg daily. However, there were
some clues to predict which patients would develop toxicity.
Pulmonary function tests showed that the baseline diffusion
capacity was lower (80 ± 17%) prior to the drug in the
group with certain pulmonary toxicity than in the remaining
patients (98 ± 26%). If the baseline diffusion capacity was
80% or less of predicted. 47% of these patients had wors-
ening of chest X-ray findings. and 25% of patients had
worsening symptoms. For those patients whose baseline
diffusion capacity was greater than 80% of predicted. only
6% had worsening of chest X-ray findings and II % had
worsening sypmtoms.
In our larger series of all of the fi rst 130 consecutive
patients (which includes the first 70 patients report ed here
in detail), there were seven certain cases of pulmonary tox-
icity and six possible cases. The two additional cases of
certain pulmonary toxicity in the second series of 60 patients
were observed in patients who had been taking 7.5 and 8.5
mg/kg. respectively. amiodarone maintenance dose daily.
They had been treated with the drug for 2 and 3 months.
respectively. Initial diffusion capacity was below 80o/e in
both. 79% in one and 70% in the other. One of these two
patients died. He presented with what appeared to be pul-
monary edema that did not clear with vigorous diuresis.
After diuresis. there were peripheral lower lung field infil-
trates on X-ray examination persisting for weeks with dif-
fuse rales. Amiodarone therapy was stopped. Recurrentven-
tricular tachycardia had returned approximately 6 weeks
after the amiodarone had been stopped, and 2 weeks later
the patient died of progressive congestive heart failure as
he was being treated with other antiarrhythmic agents. On
postmortem examination he likewise had alveolar septal and
interstitial thickening compatible with pulmonary fibrosis
due to amiodarone. In addition. he had diffuse proliferation
of alveolar cells obliterating many of the air spaces.
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After Arruodarone
Before Last
Arruodarone I Mo p 3 Mo p 9 Mo p Value* p
T. (4.1 to 11.3 J,lg%t ) 7.0 ± 1.7 8.8 ± 2.3 < 0.001 8.4 ± 3.0 < 0.02 8.5 ± 3.0 < 0.02 8.6 ± 2.5 < 0.001
TJ (33 to 45%t ) 42 ± 6 40 ± 6 NS 40 ± 6 NS 39 ± 6 < 0.05 40 ± 6 NS
TSH « 6.5 J,lUlml*) 7.4 ± 8.7 13.1 ± 17.5 NS 21.5 ± 36.9 < 0.D25 18.8 ± 26.3 < 0.05 13.8 ± 19.0 < 0.025
* Final determination in follow-up. t Normal value.
NS = not significant; p = probability value compared with data obtained before armodarone: T4 = thyroxine measured by radioimmunoassay; TJ
= triiodothyronine measured by resin uptake; TSH = thyroid stimulating hormone.
In all patients who had definite or suspected pulmonary
toxicity. amiodarone administration was at least transiently
discontinued . In one patient, amiodarone was reinstituted
at 100 mg daily 2 months later when his evidence for pul-
monary toxicity had disappeared and arrhythmias began to
recur. This patient remainson that dose, free of arrhythmias
and free of evidence of recurrence of pulmonary toxicity
for 2 months.
Thyroid function. Table 8 summarizes the effect of long-
term amiodarone therapy on thyroid function . Before amio-
darone, serum thyroxine (T4 ) was 7.0 ± 1.7 f.Lg%, in-
creasing consistentlyin most patients by I month of therapy
and remaining elevated. The serum triiodothyronine (TJ ) at
control was normal and decreased slightly. signifi cant only
at 9 months. The thyroid stimulating hormone was slightly
elevated in the group as a whole before arniodarone, and it
increased progressively throughout the duration of therapy.
It is common that this hormone is slightly elevated in pa-
tients with severe debilitating disease, but it increased dra-
matically in some patients, greater than 100 f.LU/ml in three
patients.
Clinicallyevident hypothyroidism was seen in only three
patients. with some symptoms questionably related to hy-
pothyroidism in an additional three patients. No patients
developed clinically evident hyperthyroidism.
Corneal microdeposits. Figure 4 illustrates the per-
centage of patients whose slit lamp examinations were pos-
itive at various times during follow-up. Almost all patients
eventually developcorneal microdeposits, with the majority
of patients having deposits visible between the second and
third months . The earliest deposits were seen at 5 weeks,
and the only patient who did not develop corneal micro-
deposits on long-term follow-up was also the only patient
in the series who wore contact lenses. Ocular side effects
were common, but mild. Patients most frequently com-
plained of halos visible around bright lights at night. and
some patients also complained of a gritty sensation in the
eyes or itching, dryness or photophobia.
Hepatic function tests. Though there was a trend to-
ward elevation of serum enzymes, the variability from pa-
tient to patient was quite dramatic, and there were no sta-
tistically significant differences between values before or
after amiodarone therapy. Serum bilirubin was unchanged:
0.5 ± 0.3 mg% before and 0.6 :±: 0.4 mg% after arnio-
darone. Serum alkaline phosphatase rose only from 82 ±
36 to 99 ± 57 Uzliter. SGOT rose from 22 ± 13 to 93 ±
391 Uzliter, but the standard deviation was large enough
that this value did not reach statistical significance at the p
< 0.05 level. SGPT increased from 26 ± 20 to 36 ± 21
U/liter, and LDH increased from 227 ± 80 to 353 ± 342
U/liter. Many of the baseline hepatic function values were
elevated. perhaps in some cases because patients were
undergoing repeated DC cardioversion and resuscitation im-
mediately before the initiation of amiodarone.
No patient developed clinically significant hepatic dys-
fun ction . One patient who started with hepatic precoma
exhibited further deterioration of his hepatic function over
the course of therapy. It is uncertain whether this deterio-
ration was secondary to the natural course of his disease or
Figure 4. Percent of patients with corneal microdeposits versus
time. Most patients had deposits at 3 months.
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the amiodarone. His initial bilirubin was 1.6 mg%, increas-
ing to 2.9 mg% after 2 months of therapy. Alkaline phos-
phatase was 185 U/liter, increasing to 278 U/liter after ther-
apy. SaOT increased from 24 to 32 U/liter, and SaPT was
unchanged at24 Ulliter before and22U/liter afteramiodarone.
Drug interactions. Concomitantadministration of other
cardiac drugs was common in patients treated with amio-
darone. Because many patients were having on-going ar-
rhythmias, conventional antiarrhythmicagents were usually
continued during the amiodarone loading phase to provide
at least an element of antiarrhythmic protection. We found
interactions with a number of other cardiac drugs. as re-
ported elsewhere by us (21)and byotherinvestigators (24-30).
We found that amiodarone decreases dosage requirements
for digitalis. quinidine, procainamide and Coumadin (Table
9).
Only one patient whose digitalis levels were elevated
developed symptoms and signs of toxicity which included
nausea, vomiting and bradycardia. Though patients com-
monly demonstrated electrocardiographic manifestations of
elevated quinidine or procainamide levels (widened QRS
complexes. long QT intervals or bradycardia) , only five
patients developed symptoms of quinidine toxicity and one
developed symptomsof procainamidetoxicity. No bleeding
occurred with prolongation of prothrombin time, but dos-
ages of Coumadin were adjusted promptly.
Subjective side effects. Table 10outlines the subjective
side effects experiencedby patients, classifiedas mild, mod-
erate or severe. Most common subjective side effects were
related to the gastrointestinal tract. Constipation or obsti-
pation occurred in 39 patients. Seven patients had nausea,
five had anorexia and five had ageusia.
Neurologic symptoms most commonly consisted of tremor
(17 patients), ataxia (11 patients) and dizziness (8 patients).
At times these symptoms were devastating, requiring ter-
mination of the drug. A few patients experienced a variety
of other neurologic side effects including memoryloss, ver-
tigo, headache, myoclonus, hemiballismus and peripheral
neuropathy.
Cutaneousmanifestations wereseen in 32 patients, which
usually consisted of photosensitivity or itching. Patients
Table 9. Drug Interactions With Amiodarone
No. % Increase % Dose
Drug Patients in Serum Level" Reduction Required f
Digitalis 4 280 50
Quinidine II 32 37
Procainamide 12 57 20
Coumad in II 43
" At constant drug dose. t To maintain constant serum level.
commonly had to use a sunscreen to prevent sunburn, and
some patients described a " crawling" or "prickling" sen-
sation beneath the skin. One patient developed hyperkera-
toses, and another two patients were aware of a dark blue
skin discoloration. A milder slate blue discoloration was
evident to physicians in two additional patients, but it was
not noticed by the patients or their families.
Other subjective side effects included epididymitis in seven
patients. requiring temporary discontinuation of amiodarone
in four patients and subsequent dose reduction in all.
Thus , ofthe 70 patients reported in this series, 65 patients
had subjective side effects . Only one patient in the entire
series has both continued to take amiodarone without ever
developingany subjectiveside effects and has remained free
of arrhythmias.
Discussion
The ideal antiarrhythmic agent is still unavailable. An
ideal agent should be efficacious, well tolerated with few
side effects, have a long half-life and infrequent dosing
intervals, a high therapeutic to toxic ratio, should not affect
other organ systemsor be affectedby diseasesof other organ
systems and should be relatively inexpensive. Amiodarone
fails these strict criteria because of its frequent side effects.
Dosage of amiodarone. Sideeffects of arniodarone, given
according to the dosage schedule outlined, are almost uni-
versalbut fortunately often minor. At the time that this study
was initiated, recommendations for amiodarone dosagewere
generally larger than recommendations made today (31 ,32),
and it is possible that many of the side effects could be
avoided by using lower doses of the drug. However, choos-
ing the proper dose of this drug is difficult. The lowest
possible dose should be used to attempt to limit side effects,
but on the other hand, the dose should be kept high enough
for optimal arrhythmia control. In patients with severe ven-
tricular arrhythmias, the first evidence for an inadequate
dose can be the appearance of sudden cardiac death. Even
with the relatively large maintenance dose used in this study
(with its attendant side effects) there were six recurrences
of ventricular fibrillation and five recurrences of sustained
ventricular tachycardia in the total group (including those
patients who stopped the drug).
A major limitation of amiodarone is the time required
for the drug to become effective. One study (5) reported that
the antiarrhythmic effect appeared at approximately 9 days.
Patients with recurrent, life-threatening ventricular arrhyth-
mias need control more quickly, and it is possible that the
full effect of amiodarone cannot be obtained for 1 to 2
monthsafter the drug therapyhas been started. Someauthors
(33) suggest that this problem may be obviated by starting
with the intravenous drug. Patients in our series had to
remain in the hospital on a cardiac monitor until we were
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Mild Moderate Severe
+ ::': + ::': + ::':
Gastrointestinal
Constipation 33 4 1
Obstipation 1
Nausea 3 I
Anorexia 1 2
Ageusia 2 2
Ocular
Halo effect 17
Blurred vision 5
Eye itching. dryness 10
Photophobia 8
Cardiovascular
Postural hypotension I
Bradycardia 2 3
Worsening CHF 6 2
Pulmonary
Dyspnea on exertion with
pulmonary infiltrates 7
Neurologic
Headache 1
Dizziness I 3 3
Ataxia 4 5 2
Vertigo I 3
Short-term memory loss 2 2 2
Myoclonus-abdominal
Tremor 14
Hemiballismus
Paresthesias-peripheral neuropathy
Endocrine
Hypothyroidism 2 2
Parotid swelling
Cutaneous
Photosensitivity 16
with rash 7
Change in skin color 2
Hyperkeratoses
Itching 3 2
Miscellaneous
Interrupted sleep pattern to 2
Fatigue 3 2
Depression 2 I
Exercise tolerance 3 2
Epididymitis 7
CHF = congestive heart failure; Mild noticeable. does not interfere with routine activities; Moderate = bothersome. requiring dose adjustment
and/or supplemental therapy; Severe = may necessitate cessation of amiodarone: + = amiodarone-related: ::': = ? amiodarone-related; - = doubt
amiodarone-related .
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certain that the drug had accumulated sufficiently to have a
therapeutic effect, usually a minimum of 7 to IO days. If a
patient developed ventricular tachycardia or ventricular fi-
brillation again during this time the drug was simply con-
tinued at high dose for longer periods of time .
Both initial and maintenance doses of the drug are dif-
ficult to establish . The decision that loading has been suf-
ficient and that the dose should be reduced is aided by several
clues. Measurement of amiodarone serum levels is generally
unobtainable in most hospitals . Measurement of reverse T3
has been reported to be useful in determining when the drug
has accumulated sufficiently (34). However, we most often
used suppress ion of ambient ventricular arrhythmias and
other electrocardiographic effects such as prolongation of
the PR and QT intervals, widening of the QRS and devel-
opment of sinus bradycardia and large U waves as indexes
of drug effect. Documentation of corneal microdeposits is
another clue that the drug has accumulated sufficiently, though
keratopathy usually occurs after the antiarrhythmic effect
has been achieved. Initially, the maintenance dose of amio-
darone in our patients was a mean of 572 mg per day. More
recently, the mean maintenance dose for patients who have
taken the drug for at least 3 month s has been 327 mg per
day .
Our overall approach to the use of the drug has changed
dramatically . With the first 70 patients the doses were re-
duced only if side effects were either moderate or severe.
More recently, we have been routinely decreasing the dose
before the appearance of side effects in an attempt to main-
tain a daily dose of 200 to 400 mg. Patient s with supra-
ventricular arrhythmias or less life-threatening arrhythmias
may be controlled by giving even lower doses and thus
further minimizing the possibility of side effects.
Antiarrhythmic efficacy. Amiodarone has been used in
the United States primarily for patients with recurrent and
refractory ventricular tachycardia and ventricular fibrilla-
tion. Amiodarone seems to be quite efficacious for suppres-
sion of ventricular arrhythmia, both simple and complex
forms (1-12) . Though convincing survival studies are still
lacking, amiodarone seems to be useful in preventing ven-
tricular tachycardia and may have a favorable effect on
mortality in patients with the sudden cardiac death syn-
drome . Only 4 of 54 of our patients had ventricular fibril-
lation on follow-up, compared with 2 of 12 patients who
had to stop amiodarone because of side effects. Though this
comparison does not constitute a controlled study, at least
the patients in both group s were selected for use of the drug
by the same criteria, the one group having amiodarone dis-
continued simply because of noncardiac side effects and not
becau se of antiarrhythmic inefficacy. Obviously, controlled
randomized studie s are needed to define the precise role of
amiodarone in preventing recurrences of sudden cardiac death.
We did not recognize worsenin g of ventricular arrhyth-
mias with amiodaron e in any of our patients as has been
reported recently (35-39). The four patients who died sud-
denly during follow-up had been on amiodarone for long
periods of time. Amiodarone probably did not contribute to
their subsequent fatal arrhythmias.
Electrophysiologic studies and Holter ambulatory
monitoring. Our findings confirm the observations of oth-
ers (22,23) that arrhythmias are invariably inducible during
electrophysiologic testing on amiodarone therapy. Most of
our electrophysiologic studies were performed many week s
after the patient s had begun the drug, and usually the patients
had corneal microdepo sits at the time of programmed elec-
trical stimulation. Thus , amiodarone does not seem to pre-
vent the induction of ventricular arrhythmias by pacing tech-
niques, although it is possible that certain characteristics of
the arrhythmia induced might predict subsequent clinical
success or failure of this agent (40,41 ). The finding that
arrhythmias are inducible during amiodarone therapy is con-
sistent with the concept that the myocardial substrate that
could sustain an arrhythmia is still susceptible to catheter
stimulation techniques at a time when the spontaneous ar-
rhythmias are well controlled (42) . This finding may mean
that amiodarone in some way affects the trigger events or
the initiating beats responsible for the induction of spon-
taneous ventricular arrhythmias.
Likewise. determination of a good response to amioda-
rone by Holter ambulatory electrocardiographic monitoring
was difficult . Though counts of ventricular premature com-
plexes decreased in patient s who had a good response , and
the count s increased in patients who subsequently had a
recurrence of severe arrhythmias, the results were barely
statistically significant. The findings overlapped enough be-
tween patients well controlled and those who would sub-
sequently develop a recurrence of sustained ventricular
tachycardia or ventricular fibrillation that we were uncertain
when to alter therapy on the basis of results of Holter am-
bulatory electrocardiographic monitoring. In addition, the
patients with the least arrhythmia on control monitor re-
cordings seemed to have the worst outcome, making an
assessment of drug efficacy on the basis of suppre ssion of
arrhythmia even more difficult.
Ventricular function. Many of our patients entered the
study with severe conge stive heart failure. During the period
of follow-up , nine patients had worsening of the preexisting
heart failure . However, overall ejection fraction in these
patients has not systematically deteriorated with long-term
amiodarone therapy. It is unknown whether the changes in
clinical status in these nine patient s were the result of amio-
darone therapy or simply the progression of their underlying
myocardial disease. Compared with some other new an-
tiarrhythmic agents, amiodarone seems remarkably free of
depressant effects on myocardial function.
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The high mortality rate in our series of patients was most
commonly caused by nonarrhythmic deaths . Death as a re-
sult of congestive heart failure was common. Other causes
such as pulmonary embolism and recurrence of myocardial
infarction further increased the mortality in this patient group.
These findings simply emphasize the fact that many of these
patients had terminal diseases. even though their arrhyth-
mias could be well controlled.
Pulmonary toxicity. Pulmonary toxicity remains the most
serious potential common side effect of this drug. Five pa-
tients in our series of the first 70 consecutive patients de-
veloped unequivocal changes consistent with pulmonary
toxicity. One of these five patients died with pulmonary
toxicity potentiallycontributingto his death. Anotherpatient
in the series of the next 60 patients also died with changes
suggestive of pulmonary toxicity. and both patients had
pathologic findings consistent with those reported before.
Predicting which patients will develop pulmonary toxicity
has been difficult . Preexisting chronic lung disease with
depression of diffusion capacity has weakly predicted which
patients will develop pulmonary toxicity on long-term fol-
low-up. Pulmonary toxicity can appear abruptly. either early
or late dunng the therapy. and it commonly masquerades
as viral or bacterial infection or worsening congestive heart
failure. The relation to duration of therapy. maintenance
dose and total dose remains unclear. The process appears
to be a restnctive disease With thickening of pulmonary
parenchyma and obliteration of alveolar spaces by prolif-
eration of clear cells.
Effects of thyroid gland, cornea and liver. Thyroid
function tests were commonly altered with an elevation of
thyroxine (T4 ) . depression of triiodothyronine (Tj ) and el-
evation of thyroid stimulating hormone. These findings are
consistent with block by the drug of conversion of T4 to T ,.
However. only three patients were clinically hypothyroid
requiring thyroid replacement.
All patients eventually develop ed corneal microdeposits
except fo r the one patient who wore contact lenses. The
microdeposits appeared as early as 5 weeks, and most pa-
tients had developed at least some corneal deposits by 2 to
3 months of therapy. Only rarely were these patients sig-
nificantly bothered by ocular symptoms.
Changes in hepatic function paralleled those changes
reported in other serie s, although they were statisticallv
insignificant in our serie s . Many of our patients were ex-
tremely ill at the time the drug therapy was started. either
with severe congestive heart failure or recurrent need for
cardioversion or resuscitation. or both, so initial serum en-
zyme elevations were common in these patients. One patient
may have developed worsening of his preexisting severe
hepatic dysfunction.
Drug interactions. As previously reported. amiodarone
interacts witha numberof other medications used commonly
by these patients (21). Elevation of digitalis. quinidine and
procainamide levels have been documented when amioda-
rone was added to an otherwise stable regimen. In addition,
amiodarone interacts with Coumadin, prolonging the pro-
thrombin time. Initial 50% reduction of the dose of all of
these agents is now routine for us.
Subjective side effects. Subjective side effects occurred
In 930/c of patients taking 600 mg per day, but only 19%
of patients had to discontinue the drug because of these side
effects. In all of these patients in whom the drug was ul-
timately stopped. it was first discontinued and then started
at a lower dose in an attempt to continue the therapy.
Gastrointestinal side effects were most common but usu-
ally not severe. Neurologic side effects were more devas-
tating. causing dose reduction or discontinuation in many
patients. most of them early in the dosing schedule. Cuta-
neous and ocular side effects were also bothersome. but
rarely limited the use of the drug.
Therapeutic implications. Amiodarone seems to be a
useful drug for refractory arrhythmias. Its general utility
will be limited by the long time period required before the
drug has its full effect. the uncertainty of the proper dose
in an individual patient and the potentially serious side ef-
fects of a drug that appears to accumulate in many tissues.
The drug must be closely monitored in all patients. Using
a maintenance dose of 600 mg per day. virtually all patients
will have side effects. These side effects can be both both-
ersome and dangerous (43.44). with an incidence of pul-
monary toxicity between 7 and 160/('. Lower maintenance
doses are necessary to minimize side effects. but it is un-
known if the more severe side effects can be completely
eliminated by dose reduction. The toxic to therapeutic ratio
of armodarone may be closer to unity than previously ap-
preciated. Even though these patients are at risk of sudden
death. the therapeutic strategy must be changed to eliminate
side effects. Once the arrhythmia seems to be under good
control as measured by elimination of ventricular premature
complexes and spontaneous runs of ventricular tachycardia.
the dose should be progressively decreased. The physician
should monitor other factors such as the electrocardiogram,
Holter monitor recordings. triiodothyrorune (T , ) and corneal
microdeposits to maintain an adequate amiodarone effect
without allowing breakthrough arrhythmias that could ini-
tially present as sudden cardiac death.
Finally. randomized controlled studies are still needed to
define the effect of amiodarone on survival. Our comparison
of patients who continued the drug with those who had to
discontinue the drug because of extracardiac side effects
would suggest a beneficial effect of amiodarone on com-
bined suppression of recurrent ventricular tachycardia and
fibrillation. However. until better controlled survival studies
are performed. amiodarone must still be considered Simply
an unproven experimental agent with great promise.
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